RevBio's Tetranite Bone Adhesive Trial Expanded Following FDA Nod, Gains CMS Reimbursement
• RevBio received FDA approval to expand its clinical trial for Tetranite, a bone adhesive biomaterial, after demonstrating safety in initial patients.
• The trial expansion allows Tetranite's use in intradural cases like tumor resection, beyond its initial extradural cranial flap fixation application.
• CMS has approved Tetranite for medical insurance reimbursement when used instead of metal plates/screws, enabling RevBio to charge hospitals.
• Tetranite's potential to eliminate radiographic artifacts and promote osseous union could establish it as a new standard in cranial surgeries.
© Copyright 2025. All Rights Reserved by MedPath